Amneal Pharmaceuticals, Inc.(AMRX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AMRX Amneal Pharmaceuticals, Inc.

盘后交易 08-03 18:31:25 EDT

18.85

+0.53

+2.89%

盘后19.20

+0.35+1.86%

17:11 EDT

最高18.95	最低18.44	成交量248.78万
今开18.44	昨收18.32	日振幅2.78%
总市值60.13亿	流通市值33.66亿	总股本3.19亿
成交额4,672万	换手率1.39%	流通股本1.79亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"AMRX","market":"US","secType":"STK","nameCN":"Amneal Pharmaceuticals, Inc.","latestPrice":18.85,"timestamp":1785787200000,"preClose":18.32,"halted":0,"volume":2487789,"hourTrading":{"tag":"盘后","latestPrice":19.2,"preClose":18.85,"latestTime":"17:11 EDT","volume":63812,"amount":1203129.570608,"timestamp":1785791486895,"change":0.35,"changeRate":0.018568,"amplitude":0.035013},"delay":0,"changeRate":0.028930131004366873,"floatShares":178588320,"shares":318999016,"eps":0.480828,"marketStatus":"盘后交易","change":0.53,"latestTime":"08-03 18:31:25 EDT","open":18.44,"high":18.95,"low":18.44,"amount":46724259.83616,"amplitude":0.027838,"askPrice":20.84,"askSize":100,"bidPrice":18.48,"bidSize":54,"shortable":3,"etf":0,"ttmEps":0.480828,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1785801600000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1525665600000,"exchange":"NASDAQ","adjPreClose":18.32,"preHourTrading":{"tag":"盘前","latestPrice":18.49,"preClose":18.32,"latestTime":"09:29 EDT","volume":203,"amount":3804.9599350000003,"timestamp":1785763799999,"change":0.17,"changeRate":0.009279,"amplitude":0.045306},"postHourTrading":{"tag":"盘后","latestPrice":19.2,"preClose":18.85,"latestTime":"17:11 EDT","volume":63812,"amount":1203129.570608,"timestamp":1785791486895,"change":0.35,"changeRate":0.018568,"amplitude":0.035013},"volumeRatio":1.318478,"impliedVol":0.4667,"impliedVolPercentile":0.51},"requestUrl":"/m/hq/s/AMRX","defaultTab":"news","newsList":[{"id":"1189345955","title":"Amneal Pharmaceuticals 将定期贷款转为20.4亿美元，并新增4520万美元贷款——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1189345955","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189345955?lang=zh_cn&edition=full","pubTime":"2026-08-04 04:42","pubTimestamp":1785789728,"startTime":"0","endTime":"0","summary":"Amneal Pharmaceuticals 近日向美国证券交易委员会（SEC）提交文件，披露了一项重大财务调整。公司将其定期贷款转换为20.4亿美元，同时新增一笔4520万美元的定期贷款。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AMRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197788574","title":"Amneal Pharmaceuticals获美国FDA批准新增浓度与剂型，进一步扩展碘海醇注射液产品组合","url":"https://stock-news.laohu8.com/highlight/detail?id=1197788574","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197788574?lang=zh_cn&edition=full","pubTime":"2026-07-17 20:01","pubTimestamp":1784289675,"startTime":"0","endTime":"0","summary":"Amneal Pharmaceuticals, Inc.宣布，其碘海醇注射液产品组合已获得美国食品药品监督管理局（FDA）的批准，新增了多种浓度与剂型。这一批准将显著增强该公司在该造影剂市场的产品供应能力，为医疗专业人员提供更广泛的临床选择。此举不仅丰富了Amneal的产品管线，也进一步巩固了其在仿制药及专科药物领域的市场地位。公司表示，新增的规格将满足不同诊断场景下的需求，提升患者用药的可及性与灵活性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AMRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113725546","title":"美国FDA启动预审试点项目，安尼尔、Cellares、礼来、富士胶片等多家企业参与","url":"https://stock-news.laohu8.com/highlight/detail?id=1113725546","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113725546?lang=zh_cn&edition=full","pubTime":"2026-06-30 04:30","pubTimestamp":1782765004,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局的“预审”试点项目迎来了一批重量级参与者。该计划旨在优化新药和疗法的审查流程，而此次加入的安尼尔制药、Cellares、礼来、富士胶片、Kriya、协和麒麟以及再生元制药等公司，无疑为项目注入了强大的行业动力。这一举措标志着FDA在推动监管科学创新、加速潜在疗法上市方面迈出了新的一步。通过让领先的制药与生物技术公司提前介入，FDA期望能更高效地识别和解决开发过程中的关键问题，从而最终惠及等待新疗法的患者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0096364046.USD","LU2896262040.SGD","LU1814569148.SGD","LU1712237335.SGD","LU0106261372.USD","IE00B4JS1V06.HKD","SGXZ57979304.SGD","KYKOF","LU2237443978.SGD","SGXZ81514606.USD","SG9999001176.SGD","LU0158827781.USD","SG9999014898.SGD","LU2471134796.USD","LU2602419157.SGD","LU1093756168.USD","SG9999018857.SGD","LU1623119135.USD","LU2236285917.USD","SG9999015945.SGD","LU0238689110.USD","LU1057294990.SGD","LU0353189680.USD","LU2471134523.USD","LU0820561909.HKD","LU2237443465.HKD","SG9999014906.USD","REGN","SG9999017495.SGD","LU0198837287.USD","IE00BFTCPJ56.SGD","IE00BJLML261.HKD","LU2237443622.USD","LU2112291526.USD","LU1804176565.USD","LU2168564222.USD","LU2362540622.SGD","LU1868836914.USD","LU0683600562.USD","LU2089284900.SGD","SGXZ31699556.SGD","LU1323610961.USD","LU0109391861.USD","LU2168563687.JPY","LU0053666078.USD","LU0354030438.USD","BK4581","LU0354030511.USD","BK4585","LU2462157665.USD","LU1720051017.SGD","LU2491049909.HKD","LU0823416689.USD","LU2361044949.HKD","LU2362541513.USD","IE00BFSS7M15.SGD","LU0316494557.USD","LU1989771016.USD","LU2360106947.USD","LU0640476718.USD","IE0001KFT4U8.USD","SG9999018865.SGD","LU2089984988.USD","LU0889565916.HKD","LU1023059063.AUD","LU0256863811.USD","LU2023251221.USD","IE00B1BXHZ80.USD","LU2417539215.USD","LU0006306889.USD","LU1267930730.SGD","LU1127390331.HKD","LU2237443895.HKD","LU0787776722.HKD","LU0097036916.USD","BK4534","LU2357305700.SGD","LU2063271972.USD","LU0353189763.USD","LU2362541273.HKD","LU1366192091.USD","LU2756315318.SGD","IE00B7KXQ091.USD","LU2756315664.SGD","LU2211815571.USD","SGXZ99366536.SGD","ELIS","BK4007","LU0122379950.USD","LU0203202063.USD","LU2168564065.EUR","LU2750360997.AUD","IE0004445015.USD","LU0158827948.USD","LLYZ","IE00BK4W5L77.USD","LU1548497426.USD","LU1291159041.SGD","IE00BKPKM429.USD","LU2106854487.HKD","LU2471134879.HKD","LU1868837136.USD","LU2361044865.SGD","SG9999014914.USD","GB00BDT5M118.USD","AMRX","LU1868837300.USD","LU1917777945.USD","LU2324357040.USD","LU0323591593.USD","LU0109394709.USD","LU2108987350.USD","LU2271345857.HKD","LU0210536198.USD","LU0058720904.USD","LU1983299246.USD","LU0203201768.USD","LU2265009873.SGD","SG9999014880.SGD","LU1988902786.USD","IE00BFSS8Q28.SGD","LU2491050154.USD","IE00B4R5TH58.HKD","LU2213496289.HKD","LU0432979614.USD","LU2461242641.AUD","LU1868836591.USD","LU2471134952.CNY","LU0320765059.SGD","LU2168564495.EUR","LU1064131342.USD","LU0689472784.USD","IE0009355771.USD","LLY","LU2552382058.USD","BK4588","SG9999013999.USD","SG9999001176.USD","LU0385154629.USD","IE0002141913.USD","IE00BJJMRX11.SGD","LU0471298694.HKD","LU0471298777.SGD","LLII","IE00B775H168.HKD","LU2237443549.SGD","LU0964807845.USD","SG9999015986.USD","LU1069344957.HKD","LU2361045086.USD","LU2746668461.USD","LU1551013425.SGD","LU0094547139.USD","IE00B1XK9C88.USD","LU0882574055.USD","SG9999015952.SGD","LU0943347566.SGD","LU2264538146.SGD","LU2491050071.SGD","LU0823434740.USD","LU0466842654.USD","LU0823434583.USD","LU2237438978.USD","LU2111349929.HKD","FUJIF","LU2023250330.USD","LU2237443382.USD","LU0079474960.USD","BK4516","IE00BWXC8680.SGD","IE00B2B36J28.USD","ELIL","LU0133085943.USD","LU0820561818.USD","LU1551013342.USD","IE00BJJMRZ35.SGD","LU0708995401.HKD","LU0820562030.AUD","LU1035775433.USD","LU2456880835.USD","LU1629891620.HKD","LU0320765992.SGD","LU0786609619.USD","LU2089283258.USD","SGXZ51526630.SGD","LU0882574139.USD","LU1280957306.USD","LU2746668974.SGD","IE00BN29S564.USD","LU1061106388.HKD","BK4170","LU1720051108.HKD","LU0225283273.USD","LU2023250504.SGD","IE0004445239.USD","LU2552382215.SGD","LU1974910355.USD","BK4533","BK4599","LU0234572021.USD","LU0672654240.SGD","LU1232071149.USD","IE00BJJMRY28.SGD","LU2168564149.EUR","IE00BJT1NW94.SGD","LU0061475181.USD","LU0417517546.SGD","IE00BK4W5M84.HKD","SG9999015978.USD","BK4139","LU2552382132.HKD","LU2028103732.USD","LU0456855351.SGD","IE0005OL40V9.USD","LU0114720955.EUR","LU1868836757.USD","IE00BKDWB100.SGD","LU0256863902.USD","LU2087625088.SGD","LU2468319806.SGD","LU0289739699.SGD","LU0266013472.USD","LU2750360641.GBP","LU1093756325.SGD","LU1145028129.USD","LLYX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107089082","title":"Zambon与Amneal宣布Hopledo® (ipx203)获欧盟CHMP正面评价，用于治疗帕金森病伴中重度运动波动成人患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1107089082","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107089082?lang=zh_cn&edition=full","pubTime":"2026-06-29 15:03","pubTimestamp":1782716600,"startTime":"0","endTime":"0","summary":"Zambon公司与Amneal Pharmaceuticals, Inc.联合宣布，其合作研发的药物Hopledo® (ipx203)已获得欧洲药品管理局人用药品委员会（CHMP）的正面评价。该药物适用于治疗患有帕金森病并伴随中度至重度运动波动的成人患者。\n此次CHMP的积极意见是基于关键性临床试验的有利数据，表明ipx203在控制运动症状波动方面具有潜在疗效。若后续获得欧盟委员会正式批准，该疗法将为帕金森病患者提供一种新的治疗选择。\n运动波动是帕金森病进展过程中常见的并发症，可能导致患者在日常活动中经历不可预测的运动功能变化。新药的研发进展有望帮助改善这类患者的生活质量与症状管理。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AMRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152014805","title":"Amneal公布Elevate-Pd研究全部受试者中期4期结果，进一步证实Crexont®在帕金森病中的既定疗效","url":"https://stock-news.laohu8.com/highlight/detail?id=1152014805","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152014805?lang=zh_cn&edition=full","pubTime":"2026-06-05 20:01","pubTimestamp":1780660867,"startTime":"0","endTime":"0","summary":"Amneal Pharmaceuticals, Inc. 近日公布了其Elevate-Pd研究针对完整受试者人群的中期4期试验结果。该数据进一步强化了先前已报告的关于其药物Crexont®在治疗帕金森病方面所带来的临床获益。这些发现为该疗法的有效性和安全性提供了更全面的证据支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135006950","title":"Amneal制药上调全年调整后利润预期并达成11亿美元收购协议 盘前股价跃升3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1135006950","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135006950?lang=zh_cn&edition=full","pubTime":"2026-04-22 18:45","pubTimestamp":1776854727,"startTime":"0","endTime":"0","summary":"Amneal Pharmaceuticals, Inc. 周二盘前交易中股价上涨3%，此前该公司宣布两项重大利好消息：上调2024年度调整后利润预期，以及以11亿美元收购Kashiv Biosciences的战略协议。与此同时，Amneal达成的这项价值11亿美元的全现金交易，旨在通过获得Kashiv Biosciences在研的创新型生物制剂平台，显著增强其专科药产品管线。市场分析师指出，这两项举措的协同效应可能为Amneal带来长期价值提升。交易完成后，Kashiv的研发团队将并入Amneal的创新部门，加速下一代疗法的商业化进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AMRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169032311","title":"Kashiv Biosciences与Amneal Pharmaceuticals达成收购协议，共筑全球生物类似药一体化领导者","url":"https://stock-news.laohu8.com/highlight/detail?id=1169032311","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169032311?lang=zh_cn&edition=full","pubTime":"2026-04-22 18:18","pubTimestamp":1776853081,"startTime":"0","endTime":"0","summary":"Kashiv Biosciences已同意被Amneal Pharmaceuticals收购，此举旨在打造一家完全一体化的全球生物类似药领域领导者。该交易将整合双方在研发、生产和商业化方面的优势资源，形成强大的协同效应。\n通过此次战略合并，新实体将具备覆盖生物类似药全价值链的能力，从早期开发到全球市场推广，进一步增强其在快速增长的生物制药市场的竞争力。市场观察人士认为，这一整合将重塑行业格局，为患者提供更多可负担的高质量治疗方案。\n交易的财务细节和具体时间表尚未披露，预计将在满足惯例成交条件后完成。双方管理层均对合并后的发展前景表示乐观，认为这将加速创新疗法的可及性，创造长期可持续的价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126361163","title":"安尼尔制药全年营收展望：30.5-31.5亿美元，略超IBES预估的30.97亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1126361163","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126361163?lang=zh_cn&edition=full","pubTime":"2026-04-22 18:06","pubTimestamp":1776852373,"startTime":"0","endTime":"0","summary":"安尼尔制药公司公布最新财务指引，预计本财年总营收将介于30.5亿至31.5亿美元区间。这一预测范围略高于行业研究机构IBES此前发布的30.97亿美元营收预估中值，显示出公司对业务增长持谨慎乐观态度。\n相较于市场预期，安尼尔制药设定的营收目标区间上沿具有明显优势，下沿则相对保守，反映出管理层在复杂市场环境中对业绩弹性的综合考量。该公司作为仿制药领域的重要参与者，其营收指引的微妙差异或暗示着行业供需动态的潜在变化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141266068","title":"安尼尔制药：交易有望通过消除2030年前到期里程碑与版权金义务实现重大财务协同效应","url":"https://stock-news.laohu8.com/highlight/detail?id=1141266068","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141266068?lang=zh_cn&edition=full","pubTime":"2026-04-22 18:03","pubTimestamp":1776852201,"startTime":"0","endTime":"0","summary":"安尼尔制药近日达成一项重要协议，预计将为企业带来显著的财务协同效益。该交易的核心优势在于，能够彻底免除公司在2030年之前需要履行的各类里程碑付款及版权金义务。\n通过这项战略性安排，企业将有效释放原定用于支付相关款项的财务资源，优化现金流管理。这不仅有助于提升短期财务灵活性，更为长期战略投资和业务拓展创造了有利条件。\n业内人士分析，此项协议的结构设计体现了公司对未来财务规划的深度考量。消除中长期财务负担后，企业可将更多资金投入到研发创新与市场扩张中，从而巩固其在制药领域的竞争优势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AMRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111806470","title":"Amneal同意收购Kashiv Biosciences打造全球生物类似药领导者 公布2026年第一季度强劲初步财报并上调2026财年独立指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1111806470","media":"美股速递","labels":["corporation","dataReport","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111806470?lang=zh_cn&edition=full","pubTime":"2026-04-22 18:00","pubTimestamp":1776852019,"startTime":"0","endTime":"0","summary":"Amneal Pharmaceuticals, Inc.已达成协议收购Kashiv Biosciences，此举旨在打造全球生物类似药领域的领军企业。公司同时公布了2026年第一季度的强劲初步财务业绩，并基于此上调了2026财年的独立业绩指引。此次战略收购将显著增强Amneal在生物类似药领域的研发能力和产品管线。通过与Kashiv Biosciences的整合，公司计划加速推进其生物类似药产品的商业化进程，巩固在全球医药市场的竞争地位。2026年第一季度的初步财务数据显示，公司营收和利润均实现显著增长，超出市场预期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,dataReport,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163494727","title":"Amneal公布Crexont®治疗帕金森病第四阶段Elevate-Pd研究最新积极中期结果：从Rytary®转用后每日\"良好状态\"时间延长超3小时","url":"https://stock-news.laohu8.com/highlight/detail?id=1163494727","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163494727?lang=zh_cn&edition=full","pubTime":"2026-04-20 20:03","pubTimestamp":1776686625,"startTime":"0","endTime":"0","summary":"Amneal Pharmaceuticals公司近日披露了其药物Crexont®针对帕金森病治疗的第四阶段Elevate-Pd研究的补充积极中期数据。最新结果显示，当患者从现有治疗药物Rytary®转用Crexont®后，每日能够获得超过3小时的额外\"良好状态\"时间。这一数据进一步验证了Crexont®在改善帕金森病患者日常生活质量方面的显著疗效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AMRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195137127","title":"Amneal制药在美国推出硫酸沙丁胺醇和二丙酸倍氯米松HFA吸入气雾剂","url":"https://stock-news.laohu8.com/highlight/detail?id=1195137127","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195137127?lang=zh_cn&edition=full","pubTime":"2026-04-14 20:10","pubTimestamp":1776168630,"startTime":"0","endTime":"0","summary":"Amneal Pharmaceuticals, Inc. (NYSE: AMRX) 宣布在美国市场正式推出硫酸沙丁胺醇和二丙酸倍氯米松HFA吸入气雾剂。这两种吸入制剂将为哮喘和慢性阻塞性肺疾病患者提供新的治疗选择。\n硫酸沙丁胺醇作为短效β2受体激动剂，能快速缓解支气管痉挛症状；而二丙酸倍氯米松作为吸入性皮质激素，则适用于哮喘的长期控制治疗。此次新品上市标志着该公司在呼吸系统疾病治疗领域的产品线拓展取得重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AMRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139793153","title":"Amneal制药：因0.7%氯化钠注射液中混入氨甲环酸而启动产品召回","url":"https://stock-news.laohu8.com/highlight/detail?id=1139793153","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139793153?lang=zh_cn&edition=full","pubTime":"2026-03-25 04:28","pubTimestamp":1774384096,"startTime":"0","endTime":"0","summary":"Amneal Pharmaceuticals, Inc.宣布对特定批次的0.7%氯化钠注射液（10毫克/毫升）实施紧急召回。此次行动源于生产过程中发现个别产品可能意外混入了氨甲环酸成分。\n公司声明称，尽管目前尚未收到相关不良反应报告，但为保障患者用药安全，决定主动召回受影响批次。氨甲环酸作为止血药物，若被误用于需限制凝血功能的患者，可能存在潜在健康风险。\nAmneal已启动全面质量审查，并承诺加强与分销商及医疗机构的协同处理，确保问题产品迅速撤出流通渠道。本次召回涉及产品均标注明确批号，建议使用单位立即核对库存并联系厂商退货流程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108382301","title":"Amneal制药自愿召回一批硫酸镁注射液","url":"https://stock-news.laohu8.com/highlight/detail?id=1108382301","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108382301?lang=zh_cn&edition=full","pubTime":"2026-03-25 04:26","pubTimestamp":1774383971,"startTime":"0","endTime":"0","summary":"Amneal Pharmaceuticals, Inc.宣布自愿召回一批特定批次的硫酸镁注射液（USP标准，4克/100毫升，静脉输液袋），召回范围将覆盖至医院层面。此次召回涉及的产品为注射用水中硫酸镁制剂，规格为4克/100毫升的静脉输液袋。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AMRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161811979","title":"财报前瞻 ｜Amneal Pharmaceuticals, Inc.本季度营收预计增14.18%，机构观点偏多","url":"https://stock-news.laohu8.com/highlight/detail?id=1161811979","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161811979?lang=zh_cn&edition=full","pubTime":"2026-02-20 10:10","pubTimestamp":1771553447,"startTime":"0","endTime":"0","summary":"Amneal Pharmaceuticals, Inc.将于2026年02月27日发布最新财报，市场关注营收与每股收益的增长韧性以及利润质量的修复迹象。市场一致预期本季度Amneal Pharmaceuticals, Inc.营收为8.08亿美元，同比增14.18%；调整后每股收益为0.19美元，同比增21.05%；息税前利润为1.47亿美元，同比增5.37%；公司在上一季度的公开信息中未披露对本季度毛利率、净利率或净利润的具体指引。从已披露的机构观点来看，市场呈现偏多态势：2026年01月07日，Truist Securities将Amneal Pharmaceuticals, Inc.目标价由14.00美元上调至15.00美元并维持买入评级。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻 ｜Amneal Pharmaceuticals, Inc.本季度营收预计增14.18%，机构观点偏多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119683393","title":"异动解读 | AMRX盘中大跌8.65% 利润增长放缓引发对未来获利能力担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1119683393","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119683393?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:59","pubTimestamp":1740754782,"startTime":"0","endTime":"0","summary":"Amneal Pharmaceuticals今日盘中股价大跌8.65%,引发市场广泛关注。公司近期公布的2024年第四季度财报显示,尽管销售额同比大涨18.4%至7.3052亿美元,高于市场预期,但每股收益仅为0.12美元,同比下滑14.3%,低于预期的0.15美元。利润增长乏力引发了投资者对公司未来获利能力的担忧。但投资者似乎暂时仍没有从最新财报中获得足够信心,导致AMRX股价今日承压大跌。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AMRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514934715","title":"Amneal Pharmaceuticals(AMRX.US)：2024年Q4财报实现营收7.305亿美元，前值为6.17亿美元，预期值为7.081亿美元；每股收益为0.12美元，前值为0.14美元，预期值为0.15美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514934715","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514934715?lang=zh_cn&edition=full","pubTime":"2025-02-28 19:11","pubTimestamp":1740741099,"startTime":"0","endTime":"0","summary":"Amneal Pharmaceuticals(AMRX.US)：2024年Q4财报实现营收7.305亿美元，前值为6.17亿美元，预期值为7.081亿美元；每股收益为0.12美元，前值为0.14美元，预期值为0.15美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/28191148462273.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["AMRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109132024","title":"Amneal制药公司2024年第四季度调整后每股收益$0.12，低于预期$0.15，销售额$7.3052亿，超出预期$7.0755亿","url":"https://stock-news.laohu8.com/highlight/detail?id=1109132024","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109132024?lang=zh_cn&edition=full","pubTime":"2025-02-28 19:09","pubTimestamp":1740740982,"startTime":"0","endTime":"0","summary":"Amneal制药公司报告季度每股收益为$0.12，比分析师一致预期的$0.15低20%。这比去年同期每股收益的$0.14减少了14.29%。公司报告季度销售额为$7.3052亿，比分析师一致预期的$7.0755亿高3.25%。以上内容来自Benzinga Earnings专栏，原文如下：Amneal Pharmaceuticals  reported quarterly earnings of $0.12 per share which missed the analyst consensus estimate of $0.15 by 20 percent. This is a 14.29 percent decrease over earnings of $0.14 per share from the same period last year.  The company reported quarterly sales of $730.52 million which beat the analyst consensus estimate of $707.55 million b","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Amneal制药公司2024年第四季度调整后每股收益$0.12，低于预期$0.15，销售额$7.3052亿，超出预期$7.0755亿","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2505435070","title":"Amneal Pharmaceuticals, Inc.盘中异动 股价大涨5.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2505435070","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2505435070?lang=zh_cn&edition=full","pubTime":"2025-01-24 00:14","pubTimestamp":1737648855,"startTime":"0","endTime":"0","summary":"北京时间2025年01月24日00时14分，Amneal Pharmaceuticals, Inc.股票出现异动，股价快速拉升5.16%。Amneal Pharmaceuticals, Inc.股票所在的制药行业中，整体涨幅为0.19%。其相关个股中，Eton Pharmaceuticals, Inc.、阿玛琳、大自然药业涨幅较大，Inmed Pharmaceuticals Inc.、Incannex Healthcare Inc.、Painreform Ltd.较为活跃，换手率分别为18.91%、7.61%、6.74%，振幅较大的相关个股有Gelteq Limited、Inmed Pharmaceuticals Inc.、Im Cannabis Corp.，振幅分别为12.89%、12.50%、10.12%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250124001415a22d1f36&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250124001415a22d1f36&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AMRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.amneal.com;investors.amneal.com","stockEarnings":[{"period":"1week","weight":0.0223},{"period":"1month","weight":0.0796},{"period":"3month","weight":0.4279},{"period":"6month","weight":0.3392},{"period":"1year","weight":1.3427},{"period":"ytd","weight":0.454}],"compareEarnings":[{"period":"1week","weight":0.011},{"period":"1month","weight":0.0017},{"period":"3month","weight":0.0366},{"period":"6month","weight":0.0796},{"period":"1year","weight":0.1819},{"period":"ytd","weight":0.0955}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Amneal Pharmaceuticals, Inc.是特拉华州的一家公司。该公司是一家多元化的全球性生物制药企业，开发、制造、营销和分销广泛的药品组合。它通过三个部门运营：普药部门，包括零售仿制药和注射剂；特药部门，专注于中枢神经系统和内分泌疾病的品牌药；以及AvKARE部门，为美国政府及零售市场提供分销服务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.008492},{"month":2,"riseRate":0.75,"avgChangeRate":0.016211},{"month":3,"riseRate":0.375,"avgChangeRate":-0.030057},{"month":4,"riseRate":0.375,"avgChangeRate":0.004007},{"month":5,"riseRate":0.625,"avgChangeRate":0.023823},{"month":6,"riseRate":0.333333,"avgChangeRate":0.026134},{"month":7,"riseRate":0.555556,"avgChangeRate":-0.013781},{"month":8,"riseRate":0.625,"avgChangeRate":0.036251},{"month":9,"riseRate":0.375,"avgChangeRate":-0.005103},{"month":10,"riseRate":0.75,"avgChangeRate":0.012362},{"month":11,"riseRate":0.5,"avgChangeRate":0.037801},{"month":12,"riseRate":0.625,"avgChangeRate":0.062319}],"exchange":"NASDAQ","name":"Amneal Pharmaceuticals, Inc.","nameEN":"Amneal Pharmaceuticals, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Amneal Pharmaceuticals, Inc.(AMRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Amneal Pharmaceuticals, Inc.(AMRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Amneal Pharmaceuticals, Inc.,AMRX,Amneal Pharmaceuticals, Inc.股票,Amneal Pharmaceuticals, Inc.股票老虎,Amneal Pharmaceuticals, Inc.股票老虎国际,Amneal Pharmaceuticals, Inc.行情,Amneal Pharmaceuticals, Inc.股票行情,Amneal Pharmaceuticals, Inc.股价,Amneal Pharmaceuticals, Inc.股市,Amneal Pharmaceuticals, Inc.股票价格,Amneal Pharmaceuticals, Inc.股票交易,Amneal Pharmaceuticals, Inc.股票购买,Amneal Pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Amneal Pharmaceuticals, Inc.(AMRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Amneal Pharmaceuticals, Inc.(AMRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}